Expression of SGLT1 in Human Hearts and Impairment of Cardiac Glucose Uptake by Phlorizin during Ischemia-Reperfusion Injury in Mice

Objective Sodium-glucose cotransporter 1 (SGLT1) is thought to be expressed in the heart as the dominant isoform of cardiac SGLT, although more information is required to delineate the subtypes of SGLTs in human hearts. Moreover, the functional role of SGLTs in the heart remains to be fully elucidated. We herein investigated whether SGLT1 is expressed in human hearts and whether SGLTs significantly contribute to cardiac energy metabolism during ischemia-reperfusion injury (IRI) via enhanced glucose utilization in mice. Methods and Results We determined that SGLT1 was highly expressed in both human autopsied hearts and murine perfused hearts, as assessed by immunostaining and immunoblotting with membrane fractionation. To test the functional significance of the substantial expression of SGLTs in the heart, we studied the effects of a non-selective SGLT inhibitor, phlorizin, on the baseline cardiac function and its response to ischemia-reperfusion using the murine Langendorff model. Although phlorizin perfusion did not affect baseline cardiac function, its administration during IRI significantly impaired the recovery in left ventricular contractions and rate pressure product, associated with an increased infarct size, as demonstrated by triphenyltetrazolium chloride staining and creatine phosphokinase activity released into the perfusate. The onset of ischemic contracture, which indicates the initiation of ATP depletion in myocardium, was earlier with phlorizin. Consistent with this finding, there was a significant decrease in the tissue ATP content associated with reductions in glucose uptake, as well as lactate output (indicating glycolytic flux), during ischemia-reperfusion in the phlorizin-perfused hearts. Conclusions Cardiac SGLTs, possibly SGLT1 in particular, appear to provide an important protective mechanism against IRI by replenishing ATP stores in ischemic cardiac tissues via enhancing availability of glucose. The present findings provide new insight into the significant role of SGLTs in optimizing cardiac energy metabolism, at least during the acute phase of IRI.

[1]  P. Gunning,et al.  Tropomodulin3 is a novel Akt2 effector regulating insulin-stimulated GLUT4 exocytosis through cortical actin remodeling , 2015, Nature Communications.

[2]  Yu Hasegawa,et al.  Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice , 2014, Cardiovascular Diabetology.

[3]  T. Minamino,et al.  Arachidonate 12/15-Lipoxygenase–Induced Inflammation and Oxidative Stress Are Involved in the Development of Diabetic Cardiomyopathy , 2014, Diabetes.

[4]  M. Yoshimura,et al.  Preconditioning actions of aldosterone through p38 signaling modulation in isolated rat hearts. , 2014, The Journal of endocrinology.

[5]  Ferhaan Ahmad,et al.  Transgenic Knockdown of Cardiac Sodium/Glucose Cotransporter 1 (SGLT1) Attenuates PRKAG2 Cardiomyopathy, Whereas Transgenic Overexpression of Cardiac SGLT1 Causes Pathologic Hypertrophy and Dysfunction in Mice , 2014, Journal of the American Heart Association.

[6]  Phlorizin prevents electrically-induced ventricular tachyarrhythmia during ischemia in langendorff-perfused guinea-pig hearts. , 2014, Biological & pharmaceutical bulletin.

[7]  H. Koepsell,et al.  Localizations of Na+-d-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart , 2014, Pflügers Archiv - European Journal of Physiology.

[8]  A. Tahrani,et al.  SGLT inhibitors in management of diabetes. , 2013, The lancet. Diabetes & endocrinology.

[9]  R. DeFronzo,et al.  Novel Hypothesis to Explain Why SGLT2 Inhibitors Inhibit Only 30–50% of Filtered Glucose Load in Humans , 2013, Diabetes.

[10]  Donghai Wen,et al.  Regulation of BK-α expression in the distal nephron by aldosterone and urine pH. , 2013, American journal of physiology. Renal physiology.

[11]  S. Matsuo,et al.  An Immunohistochemical Analysis of Tissue Thrombin Expression in the Human Atria , 2013, PloS one.

[12]  Juan J. Marin,et al.  MAP17 and SGLT1 Protein Expression Levels as Prognostic Markers for Cervical Tumor Patient Survival , 2013, PloS one.

[13]  E. Wright,et al.  Regional distribution of SGLT activity in rat brain in vivo. , 2013, American journal of physiology. Cell physiology.

[14]  M. Matsushima,et al.  Transient decrease in serum potassium level during ischemic attack of acute coronary syndrome: Paradoxical contribution of plasma glucose level and glycohemoglobin , 2013, Cardiovascular Diabetology.

[15]  Development of a cell-based nonradioactive glucose uptake assay system for SGLT1 and SGLT2. , 2012, Analytical biochemistry.

[16]  M. Yoshimura,et al.  Biphasic Action of Aldosterone on Akt Signaling in Cardiomyocytes , 2012, Hormone and Metabolic Research.

[17]  I. Taniguchi,et al.  The role of Na+/H+ exchanger in Ca2+ overload and ischemic myocardial damage in hearts from type 2 diabetic db/db mice , 2012, Cardiovascular Diabetology.

[18]  Richard T. Lee,et al.  Deletion of thioredoxin-interacting protein in mice impairs mitochondrial function but protects the myocardium from ischemia-reperfusion injury. , 2012, The Journal of clinical investigation.

[19]  H. Parker,et al.  Na+-d-glucose Cotransporter SGLT1 is Pivotal for Intestinal Glucose Absorption and Glucose-Dependent Incretin Secretion , 2011, Diabetes.

[20]  G. Rosano,et al.  Optimization of Cardiac Metabolism in Heart Failure , 2011, Current pharmaceutical design.

[21]  L. Bertrand,et al.  NADPH oxidase activation by hyperglycaemia in cardiomyocytes is independent of glucose metabolism but requires SGLT1. , 2011, Cardiovascular research.

[22]  S. Okamoto,et al.  An enzymatic photometric assay for 2-deoxyglucose uptake in insulin-responsive tissues and 3T3-L1 adipocytes. , 2011, Analytical biochemistry.

[23]  D. Loo,et al.  Biology of human sodium glucose transporters. , 2011, Physiological reviews.

[24]  Ferhaan Ahmad,et al.  SGLT1, a novel cardiac glucose transporter, mediates increased glucose uptake in PRKAG2 cardiomyopathy. , 2010, Journal of molecular and cellular cardiology.

[25]  H. Mächler,et al.  Glucose-transporter-mediated positive inotropic effects in human myocardium of diabetic and nondiabetic patients. , 2010, Metabolism: clinical and experimental.

[26]  R. Henry,et al.  SGLT2 inhibition — a novel strategy for diabetes treatment , 2010, Nature Reviews Drug Discovery.

[27]  B. Pieske,et al.  Functional effects of glucose transporters in human ventricular myocardium , 2010, European journal of heart failure.

[28]  S. Cook,et al.  Abnormal myocardial insulin signalling in type 2 diabetes and left-ventricular dysfunction. , 2010, European heart journal.

[29]  Ferhaan Ahmad,et al.  SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states. , 2009, Cardiovascular research.

[30]  Li Xin,et al.  Dapagliflozin, a Selective SGLT2 Inhibitor, Improves Glucose Homeostasis in Normal and Diabetic Rats , 2008, Diabetes.

[31]  A. Rosenzweig,et al.  Effects of chronic Akt activation on glucose uptake in the heart. , 2006, American journal of physiology. Endocrinology and metabolism.

[32]  K. Nakao,et al.  Direct effects of aldosterone on cardiomyocytes in the presence of normal and elevated extracellular sodium. , 2006, Endocrinology.

[33]  S. Confort-Gouny,et al.  Intracellular sodium increase and susceptibility to ischaemia in hearts from type 2 diabetic db/db mice , 2006, Diabetologia.

[34]  D. Kass,et al.  PI3K rescues the detrimental effects of chronic Akt activation in the heart during ischemia/reperfusion injury. , 2005, The Journal of clinical investigation.

[35]  M. Birnbaum,et al.  AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. , 2004, The Journal of clinical investigation.

[36]  H. Koepsell,et al.  Na(+)-D-glucose cotransporter in muscle capillaries increases glucose permeability. , 2004, Biochemical and biophysical research communications.

[37]  M. D'Andrea,et al.  Human cardiomyocytes express high level of Na+/glucose cotransporter 1 (SGLT1) , 2003, Journal of cellular biochemistry.

[38]  Mohit M. Jain,et al.  Cardiac-Specific Overexpression of GLUT1 Prevents the Development of Heart Failure Attributable to Pressure Overload in Mice , 2002, Circulation.

[39]  R. Hajjar,et al.  Akt Activation Preserves Cardiac Function and Prevents Injury After Transient Cardiac Ischemia In Vivo , 2001, Circulation.

[40]  R. Tian,et al.  Responses of GLUT4-Deficient Hearts to Ischemia Underscore the Importance of Glycolysis , 2001, Circulation.

[41]  J. Vanoverschelde,et al.  Glucose for the heart. , 1999, Circulation.

[42]  M. Smith,et al.  Cardioprotective effect of diazoxide and its interaction with mitochondrial ATP-sensitive K+ channels. Possible mechanism of cardioprotection. , 1997, Circulation research.

[43]  M. Kasahara,et al.  Characterization of rat Glut4 glucose transporter expressed in the yeast Saccharomyces cerevisiae: comparison with Glut1 glucose transporter. , 1997, Biochimica et biophysica acta.

[44]  M. Kasahara,et al.  Expression of the rat GLUT1 glucose transporter in the yeast Saccharomyces cerevisiae. , 1996, The Biochemical journal.

[45]  G. Radda,et al.  Is a high glycogen content beneficial or detrimental to the ischemic rat heart? A controversy resolved. , 1996, Circulation research.

[46]  L. Opie,et al.  Coronary flow and glucose delivery as determinants of contracture in the ischemic myocardium. , 1995, Journal of molecular and cellular cardiology.

[47]  J. Nerbonne,et al.  Glucose transport and phosphorylation in single cardiac myocytes: rate-limiting steps in glucose metabolism. , 1994, The American journal of physiology.

[48]  Tellez de Inon Mt.  Inhibition of mitochondrial ATPase by phlorizin. , 1968 .

[49]  M. T. Tellez de Iñon.  Inhibition of mitochondrial ATPase by phlorizin. , 1968, Acta physiologica latino americana.

[50]  M. Burgos,et al.  ULTRASTRUCTURE OF ISOLATED KIDNEY MITOCHONDRIA TREATED WITH PHLORIZIN AND ATP , 1964, The Journal of cell biology.